Skip to content
Clinical Trials – home
Therapeutic area

Vascular disorders – page 35

  • 838 clinical trials
  • 353 recruiting
  • 378 conditions
  • 28 countries

Conditions in this area

378 conditions with trials, the busiest first

Clinical trials in Vascular disorders

838 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

838 clinical trials

Systemic scleroderma

Not yet recruiting

Rituximab versus placebo for maintenance therapy in adults with stabilized systemic sclerosis‑associated interstitial lung disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Assistance Publique Hopitaux De Paris

Systemic scleroderma

Not yet recruiting

Lebrikizumab in Adults with Moderate to Severe Localized Scleroderma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Pre-eclampsia

Not yet recruiting

Acetylsalicylic Acid for Preventing Preeclampsia in Pregnant Women

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

Septic shock+1

Not yet recruiting

Angiotensin II in Children and Adolescents With Refractory Hypotension in Distributive Shock

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:ANGIOTENSIN II

Coronary artery disease

Not yet recruiting

A study to evaluate the effect of EA-230 on the hospital stay length for patients undergoing coronary artery bypass surgery for coronary artery disease.

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:(2S)-2-[[2-[[(2S)-5-AMINO-2-[[(2S)-2-AMINOPROPANOYL]AMINO]-5-OXOPENTANOYL]AMINO]ACETYL]AMINO]-3-METHYLBUTANOIC ACID

Deep vein thrombosis+1

Not yet recruiting

A study to evaluate the use of colchicine to reduce inflammation in patients with deep vein thrombosis.

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Universita' Degli Studi G. D'Annunzio Di Chieti

Giant cell arteritis+1

Not yet recruiting

Diagnostic Accuracy of 68Ga‑FAPI‑46 PET/CT in Patients with Suspected Giant Cell Arteritis and Polymyalgia Rheumatica

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Universitair Medisch Centrum Groningen

Diabetic foot+1

Not yet recruiting

Comparing local gentamicin or vancomycin hydrochloride to a drug combination for patients with diabetic foot osteomyelitis

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Pirkanmaan hyvinvointialue

Ischaemic stroke

Not yet recruiting

Comparison of sevoflurane and propofol for general anesthesia in patients with acute ischemic stroke undergoing mechanical thrombectomy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Propofol
  • Sponsor:Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

Cerebral haemorrhage

Not yet recruiting

Study evaluating the effect of levetiracetam on recovery in patients with intracerebral haemorrhage

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Levetiracetam
  • Sponsor:Hospices Civils De Lyon

Embolism

Not yet recruiting

A study to compare REGN7508 and acetylsalicylic acid for preventing blood clots in adults undergoing elective total knee replacement.

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Regeneron Pharmaceuticals Inc.

Migraine

Not yet recruiting

A study to evaluate the safety and effectiveness of omalizumab in adults with episodic migraine

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Omalizumab
  • Sponsor:Oslo University Hospital HF

Substances studied in this area

The therapies tested most often in Vascular disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.